Targeting the sphingosine kinase/sphingosine 1-phosphate pathway to treat chronic inflammatory kidney diseases

Basic and Clinical Pharmacology and Toxicology

Volumn 114, Issue 1, 2014, Pages 44-49

  Schwalm, Stephanie ^a,b   Pfeilschifter, Josef ^a   Huwiler, Andrea ^a,b  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC AGENT; FINGOLIMOD; GLUCOCORTICOID; RECOMBINANT PROTEIN; RECOMBINANT SPHINGOSINE 1 PHOSPHATE LYASE; SONEPCIZUMAB; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE KINASE; UNCLASSIFIED DRUG;

ATTENUATION; CELL DIVISION; CELL PROLIFERATION; CELL SURFACE; CHRONIC GLOMERULONEPHRITIS; CHRONIC KIDNEY DISEASE; DISEASE COURSE; DRUG EFFICACY; END STAGE RENAL DISEASE; EXTRACELLULAR MATRIX; FIBROBLAST; GENE TARGETING; GLOMERULONEPHRITIS; HOSPITALIZATION; HUMAN; INCIDENCE; INFLAMMATION; KIDNEY FIBROSIS; MESANGIUM CELL; MOLECULE; NEPHRITIS; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALIA;

ANIMALS; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; FIBROSIS; GLOMERULONEPHRITIS; HUMANS; INFLAMMATION; KIDNEY FAILURE, CHRONIC; LYSOPHOSPHOLIPIDS; MOLECULAR TARGETED THERAPY; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); PROPYLENE GLYCOLS; RECEPTORS, LYSOSPHINGOLIPID; SIGNAL TRANSDUCTION; SPHINGOSINE;

EID: 84890792936     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/bcpt.12103     Document Type: Review

References (53)

1. Seymour AE. Glomerulonephritis: approaches to classification. Pathology 1985;17:225-38.
2. Sethi S, Fervenza FC. Membranoproliferative glomerulonephritis-a new look at an old entity. N Engl J Med 2012;366:1119-31.
3. Migliorini A, Ebid R, Scherbaum CR, Anders HJ. The danger control concept in kidney disease: mesangial cells. J Nephrol 2013;26:437-49.
4. Pfeilschifter J. Mesangial Cells Orchestrate Inflammation in the Renal Glomerulus. News Physiol Sci 1994;9:271-6.
5. Schlöndorff D, Banas B. The mesangial cell revisited: no cell is an island. J Am Soc Nephrol 2009;20:1179-87.
6. Jo SK, Bajwa A, Awad AS, Lynch KR, Okusa MD. Sphingosine-1-phosphate receptors: biology and therapeutic potential in kidney disease. Kidney Int 2008;73:1220-30.
7. Maceyka M, Harikumar KB, Milstien S, Spiegel S. Sphingosine-1-phosphate signaling and its role in disease. Trends Cell Biol 2012;22:50-60.
8. Koch A, Pfeilschifter J, Huwiler A. Sphingosine 1-Phosphate in Renal Diseases. Cell Physiol Biochem 2013;31:745-60.
9. Hait NC, Allegood J, Maceyka M, Strub GM, Harikumar KB, Singh SK et al. Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate. Science 2009;325:1254-7.
10. Alvarez SE, Harikumar KB, Hait NC, Allegood J, Strub GM, Kim EY et al. Sphingosine-1-phosphate is a missing cofactor for the E3 ubiquitin ligase TRAF2. Nature 2010;465:1084-8.
11. Alemany R, van Koppen CJ, Danneberg K, Ter Braak M, Meyer Zu Heringdorf D. Regulation and functional roles of sphingosine kinases. Naunyn-Schmiedeberg's Arch Pharmacol 2007;374:413-28.
12. Hofmann LP, Ren S, Schwalm S, Pfeilschifter J, Huwiler A. Sphingosine kinase 1 and 2 regulate the capacity of mesangial cells to resist apoptotic stimuli in an opposing manner. Biol Chem 2008;389:1399-407.
13. Zhang H, Desai NN, Olivera A, Seki T, Brooker G, Spiegel S. Sphingosine-1-phosphate, a novel lipid, involved in cellular proliferation. J Cell Biol 1991;114:155-67.
14. Gennero I, Simon MF, Gaits F, Cariven C, Rogalle P, Fauvel J et al. Effect of sphingosine-1-phosphate and analogues of lysophosphatidic acid on mesangial cell proliferation. Ann N Y Acad Sci 2000;905:340-3.
15. Hanafusa N, Yatomi Y, Yamada K, Hori Y, Nangaku M, Okuda T et al. Sphingosine 1-phosphate stimulates rat mesangial cell proliferation from outside the cells. Nephrol Dial Transplant 2002;17:580-6.
16. Klawitter S, Hofmann LP, Pfeilschifter J, Huwiler A. Extracellular nucleotides induce migration of renal mesangial cells by upregulating sphingosine kinase-1 expression and activity. Br J Pharmacol 2007;150:271-80.
17. Katsuma S, Hada Y, Ueda T, Shiojima S, Hirasawa A, Tanoue A et al. Signalling mechanisms in sphingosine 1-phosphate-promoted mesangial cell proliferation. Genes Cells 2002;7:1217-30.
18. Xin C, Ren S, Pfeilschifter J, Huwiler A. Heterologous desensitization of the sphingosine-1-phosphate receptors by purinoceptor activation in renal mesangial cells. Br J Pharmacol 2004;143:581-9.
19. Chun J, Brinkmann V. A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya). Discov Med 2011;12:213-28.
20. Sui M, Zhou J, Xie R, Liu X, Mu S, Jia X et al. The sphingosine-1-phosphate receptor agonist FTY720 prevents the development of anti-glomerular basement membrane glomerulonephritis. Mol Biol Rep 2012;39:389-97.
21. Martini S, Kramer S, Loof T, Wang-Rosenke Y, Daig U, Budde K et al. S1P modulator FTY720 limits matrix expansion in acute anti-thy1 mesangioproliferative glomerulonephritis. Am J Physiol Renal Physiol 2007;292:F1761-70.
22. Peters H, Martini S, Wang Y, Shimizu F, Kawachi H, Kramer S et al. Selective lymphocyte inhibition by FTY720 slows the progressive course of chronic anti-thy 1 glomerulosclerosis. Kidney Int 2004;66:1434-43.
23. Awad AS, Rouse MD, Khutsishvili K, Huang L, Bolton WK, Lynch KR et al. Chronic sphingosine 1-phosphate 1 receptor activation attenuates early-stage diabetic nephropathy independent of lymphocytes. Kidney Int 2011;79:1090-8.
24. Pedregosa JF, Haidar AA, Hirata AE, Franco M, Gomes GN, Bueno V. TLR2 and TLR4 expression after kidney ischemia and reperfusion injury in mice treated with FTY720. Int Immunpharmacol 2011;11:1311-8.
25. Jo SK, Bajwa A, Ye H, Vergis AL, Awad AS, Kharel Y et al. Divergent roles of sphingosine kinases in kidney ischemia-reperfusion injury. Kidney Int 2009;75:167-75.
26. Park SW, Kim M, Brown KM, D'Agati VD, Lee HT. Inhibition of sphingosine 1-phosphate receptor 2 protects against renal ischemia-reperfusion injury. J Am Soc Nephrol 2012;23:266-80.
27. Ren S, Babelova A, Moreth K, Xin C, Eberhardt W, Doller A et al. Transforming growth factor-beta2 upregulates sphingosine kinase-1 activity, which in turn attenuates the fibrotic response to TGF-beta2 by impeding CTGF expression. Kidney Int 2009;76:857-67.
28. Natoli TA, Husson H, Rogers KA, Smith LA, Wang B, Budman Y et al. Loss of GM3 synthase gene, but not sphingosine kinase 1, is protective against murine nephronophthisis-related polycystic kidney disease. Hum Mol Genet 2012;21:3397-407.
29. Snider AJ, Orr Gandy KA, Obeid LM. Sphingosine kinase: role in regulation of bioactive sphingolipid mediators in inflammation. Biochimie 2010;92:707-15.
30. Park SW, Kim M, Kim M, D'Agati VD, Lee HT. Sphingosine kinase 1 protects against renal ischemia-reperfusion injury in mice by sphingosine-1-phosphate1 receptor activation. Kidney Int 2011;80:1315-27.
31. Snider AJ, Ruiz P, Obeid LM, Oates JC. Inhibition of sphingosine kinase-2 in a murine model of lupus nephritis. PLoS ONE 2013;8:e53521.
32. Xin C, Ren S, Kleuser B, Shabahang S, Eberhardt W, Radeke H et al. Sphingosine 1-phosphate cross-activates the Smad signaling cascade and mimics transforming growth factor-beta-induced cell responses. J Biol Chem 2004;279:35255-62.
33. Wynn TA. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest 2007;117:524-9.
34. Liu Y. Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int 2006;69:213-7.
35. El-Shewy HM, Sohn M, Wilson P, Lee MH, Hammad SM, Luttrell LM et al. Low-density lipoprotein induced expression of connective tissue growth factor via transactivation of sphingosine 1-phosphate receptors in mesangial cells. Mol Endocrinol 2012;26:833-45.
36. Perbal B. CCN proteins: multifunctional signalling regulators. Lancet 2004;363:62-4.
37. Xin C, Ren S, Eberhardt W, Pfeilschifter J, Huwiler A. The immunomodulator FTY720 and its phosphorylated derivative activate the Smad signalling cascade and upregulate connective tissue growth factor and collagen type IV expression in renal mesangial cells. Br J Pharmacol 2006;147:164-74.
38. Katsuma S, Ruike Y, Yano T, Kimura M, Hirasawa A, Tsujimoto G. Transcriptional regulation of connective tissue growth factor by sphingosine 1-phosphate in rat cultured mesangial cells. FEBS Lett 2005;579:2576-82.
39. Samarakoon R, Goppelt-Struebe M, Higgins PJ. Linking cell structure to gene regulation: signaling events and expression controls on the model genes PAI-1 and CTGF. Cell Signal 2010;22:1413-9.
40. Cencetti F, Bernacchioni C, Nincheri P, Donati C, Bruni P. Transforming growth factor-beta1 induces transdifferentiation of myoblasts into myofibroblasts via up-regulation of sphingosine kinase-1/S1P3 axis. Mol Biol Cell 2010;21:1111-24.
41. Geoffroy K, Troncy L, Wiernsperger N, Lagarde M, El Bawab S. Glomerular proliferation during early stages of diabetic nephropathy is associated with local increase of sphingosine-1-phosphate levels. FEBS Lett 2005;579:1249-54.
42. Lan T, Liu W, Xie X, Xu S, Huang K, Peng J et al. Sphingosine kinase-1 pathway mediates high glucose-induced fibronectin expression in glomerular mesangial cells. Mol Endocrinol 2011;25:2094-105.
43. Koch A, Völzke A, Wünsche C, Meyer zu Heringdorf D, Huwiler A, Pfeilschifter J. Thiazolidinedione-dependent activation of sphingosine kinase 1 causes an anti-fibrotic effect in renal mesangial cells. Br J Pharmacol 2012;166:1018-32.
44. Collins AJ, Foley RN, Herzog C, Chavers B, Gilbertson D, Herzog C et al. US Renal Data System 2012 Annual Data Report. Am J Kidney Dis 2013;61:A7.
45. Javaid B, Quigg RJ. Treatment of glomerulonephritis: will we ever have options other than steroids and cytotoxics? Kidney Int 2005;67:1692-703.
46. Schwalm S, Pfeilschifter J, Huwiler A. Sphingosine-1-phosphate: a Janus-faced mediator of fibrotic diseases. Biochim Biophys Acta 2013;1831:239-50.
47. Hoitsma AJ, Woodle ES, Abramowicz D, Proot P, Vanrenterghem Y. FTY720 combined with tacrolimus in de novo renal transplantation: 1-year, multicenter, open-label randomized study. Nephrol Dial Transplant 2011;26:3802-5.
48. Huwiler A, Pfeilschifter J. New players on the center stage: sphingosine 1-phosphate and its receptors as drug targets. Biochem Pharmacol 2008;75:1893-900.
49. Imasawa T, Kitamura H, Ohkawa R, Satoh Y, Miyashita A, Yatomi Y. Unbalanced expression of sphingosine 1-phosphate receptors in diabetic nephropathy. Exp Toxicol Pathol 2010;62:53-60.
50. Sabbadini RA. Sphingosine-1-phosphate antibodies as potential agents in the treatment of cancer and age-related macular degeneration. Br J Pharmacol 2011;162:1225-38.
51. Efficacy and Safety Study of iSONEP With and Without Lucentis/Avastin to Treat Age-related Macular Degeneration (AMD) (Nexus) [database on the Internet]. Bethesda (MD): National Library of Medicine (US). 2013. http://clinicaltrials.gov/ct2/show/record/NCT01414153?term=isonep&rank=1 (last accessed on 30 May 2013).
52. ™ to Treat Unresectable and Refractory Renal Cell Carcinoma [database on the Internet]. Bethesda (MD): National Library of Medicine (US). 2012. http://clinicaltrials.gov/ct2/show/NCT01762033?term=asonep&rank=2 (last accessed on 30 May 2013).
53. Huwiler A, Bourquin F, Kotelevets N, Pastukhov O, Capitani G, Grutter MG et al. A prokaryotic S1P lyase degrades extracellular S1P in vitro and in vivo: implication for treating hyperproliferative disorders. PLoS ONE 2011;6:e22436.